No, You Should Not Take Dapagliflozin 10 mg and Empagliflozin 10 mg Together
Taking both dapagliflozin and empagliflozin simultaneously is not recommended and provides no additional benefit. Both medications belong to the same drug class (SGLT2 inhibitors) and work through identical mechanisms—they block the same sodium-glucose cotransporter-2 protein in the kidneys 1.
Why Combining These Medications Makes No Sense
Same Mechanism, Same Target
Both drugs inhibit the exact same molecular target in your kidneys. Using both simultaneously would be like taking two different brands of the same medication—you're simply duplicating the effect rather than adding complementary benefits 2. The cardiovascular and kidney protection benefits are achieved through this single mechanism, so doubling up provides no incremental advantage.
Evidence Shows Comparable Efficacy
Recent comparative effectiveness research demonstrates that dapagliflozin and empagliflozin have equivalent cardiovascular benefits when used at clinically effective doses 3. A 2025 study analyzing over 650,000 patients found no significant difference between these agents for:
- Heart attack or stroke risk (HR 0.95-0.98 vs empagliflozin)
- Cardiovascular death
- Overall mortality 3
A prospective crossover study in heart failure patients confirmed that switching between empagliflozin 10 mg and dapagliflozin 10 mg produced no significant change in NT-proBNP levels or clinical outcomes, supporting their interchangeable use 4.
Standard Dosing Is Already Optimized
The recommended doses are 5, 1:
- Dapagliflozin: 10 mg once daily
- Empagliflozin: 10-25 mg once daily
These doses were established in major cardiovascular outcomes trials (DAPA-HF, EMPEROR-Reduced, EMPA-REG OUTCOME) and represent the optimal therapeutic effect 1, 6, 7. Taking both would not enhance glucose lowering, cardiovascular protection, or kidney benefits—it would simply increase your risk of adverse effects.
Potential Harms of Combining
Using both medications simultaneously would amplify class-specific risks without added benefit:
- Volume depletion and hypotension: Both drugs cause osmotic diuresis and natriuresis, leading to fluid loss 1
- Genital mycotic infections: Risk increases with SGLT2 inhibitor exposure 1
- Diabetic ketoacidosis: Rare but serious, particularly in insulin-deficient states 2
- Urinary tract infections: Documented with this drug class 1
- Acute kidney injury: Especially during volume-depleted states 8
The Correct Approach
Choose one SGLT2 inhibitor based on your specific indication:
For Type 2 Diabetes with Cardiovascular Disease
Select either dapagliflozin 10 mg OR empagliflozin 10 mg daily 9, 2. Both reduce major adverse cardiovascular events comparably 3.
For Heart Failure (Reduced or Preserved Ejection Fraction)
- Dapagliflozin 10 mg daily (approved for HFrEF and HFnrEF) 5, 7
- Empagliflozin 10 mg daily (approved for HFrEF and HFnrEF) 5, 7
Both reduce heart failure hospitalization and cardiovascular death with similar efficacy 10, 11. The 2025 Canadian guidelines list both as equivalent first-tier therapies 5.
For Chronic Kidney Disease
Dapagliflozin 10 mg daily is specifically indicated to reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in patients with CKD at risk of progression 12. It can be initiated down to eGFR ≥25 mL/min/1.73 m² 8, 12.
Important Caveat About Kidney Function
If you have reduced kidney function:
- Dapagliflozin: Can be initiated if eGFR ≥25 mL/min/1.73 m²; continue until dialysis for cardiovascular/kidney benefits 8, 12
- Empagliflozin: Initiation not recommended if eGFR <20 mL/min/1.73 m² for heart failure indication 8
The glucose-lowering effect diminishes below eGFR 45 mL/min/1.73 m², but cardiovascular and kidney benefits persist 8, 2.
What You Should Do Instead
Pick one SGLT2 inhibitor and optimize other complementary therapies. If you need additional cardiovascular or metabolic benefit beyond a single SGLT2 inhibitor, guidelines recommend adding medications from different drug classes 9, 2:
- GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) for additional cardiovascular benefit and weight loss 8, 9, 2
- Metformin as foundational glucose-lowering therapy if tolerated 9, 2
- ACE inhibitors/ARBs or ARNI for heart failure and kidney protection 5
- Mineralocorticoid receptor antagonists for heart failure 5
Emerging data suggest that combining an SGLT2 inhibitor with a GLP-1 receptor agonist provides complementary cardiovascular and kidney benefits because they work through different mechanisms 9. This combination makes physiologic sense—combining two drugs from the same class does not.